Investments, Funding & Disinvestment

The financing forms part of Biovac’s expansion programme, which aims to increase the company’s annual manufacturing capacity to as many as 500 million vaccine doses.

This highly specific dependence could provide an opportunity for researchers to investigate new approaches to malaria treatment by targeting the parasite’s ability to obtain or use these fats.

The company plans to construct a new three-story, 145,000-square-foot facility for drug product manufacturing and packaging next to its existing operations.

The funding round also attracted investment from the Global Innovation Fund, Africa Health Ventures and other undisclosed investors.

The renewed work aims to complete the university’s 5,300-square-metre Laboratory Complex, a project that began in 2014 but stalled for several years.

The plan includes upgrading digital infrastructure and improving the speed, reliability and quality of communication networks that support remote consultations.

Under the terms of the agreement, Lilly will pay US$6.75 per share in cash, representing a 40% premium over AtaiBeckley’s 30-day volume-weighted average share price.

Following the transaction, former Kira shareholders will own nearly 50% of the combined company, new private financing investors will hold slightly more than 43%, and existing Jasper shareholders will retain almost 7%.

The proposed Biotech Life Sciences Park will undergo a feasibility study after APIFA Biotech’s privately initiated proposal received approval to advance to the project development stage under a public-private partnership (PPP) arrangement.

The Georgetown facility includes a payload operations control center that allows Redwire to monitor and manage experiments conducted in real time aboard the International Space Station (ISS).